Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
BioMarin Pharmaceutical Inc. (BMRN) - free report >>
Casella Waste Systems, Inc. (CWST) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin Pharmaceutical Inc. (BMRN) - free report >>
Casella Waste Systems, Inc. (CWST) - free report >>
Image: Bigstock
New Strong Sell Stocks for March 18th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Advanced Energy Industries, Inc. (AEIS - Free Report) offers process power solutions. The Zacks Consensus Estimate for its current year earnings has been revised 1.3% downward over the last 30 days.
AMC Entertainment Holdings, Inc. (AMC - Free Report) owns and operates theatres. The Zacks Consensus Estimate for its current year earnings has been revised 18.8% downward over the last 30 days.
BioMarin Pharmaceutical Inc. (BMRN - Free Report) a biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 39.4% downward over the last 30 days.
Casella Waste Systems, Inc. (CWST - Free Report) is a solid waste services company. The Zacks Consensus Estimate for its current year earnings has been revised 5.9% downward over the last 30 days.
China Biologic Products Holdings, Inc. manufactures human plasma-based biopharmaceutical products. The Zacks Consensus Estimate for its current year earnings has been revised 6% downward over the last 30 days.
View the entire Zacks Rank #5 List.